or Try an Advanced Search...

    Technical Analysis for IMTX - Immatics N.V.

    Grade Last Price % Change Price Change
    F 7.83 0.38% 0.03
    IMTX closed down 0.13 percent on Wednesday, November 20, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical IMTX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.38%
    Lizard Bullish Bullish Day Trade Setup 0.38%
    Doji - Bullish? Reversal 0.38%
    Lower Bollinger Band Walk Weakness 0.38%
    New 52 Week Low Weakness 0.38%
    Down 3 Days in a Row Weakness 0.38%
    Down 4 Days in a Row Weakness 0.38%
    Down 5 Days in a Row Weakness 0.38%
    Lower Bollinger Band Touch Weakness 0.38%
    Oversold Stochastic Weakness 0.38%
    Older End-of-Day Signals for IMTX ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 2 hours ago
    Up 2% about 2 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    Lizard Bullish Entry about 3 hours ago
    Rose Above Previous Day's High about 3 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IMTX Chart by TradingView
    Basic chart:

    Profile

    Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Cancer Treatment Treatment Of Cancer Cell Therapy Virotherapy Immunotherapies T Cell Adoptive Cell Transfer

    Is IMTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
    Nov 19 Immatics Sees Revenue Surge Despite R&D Expenses
    Nov 18 Immatics GAAP EPS of -€0.11, revenue of €50.56M
    Nov 18 Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
    Nov 8 Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
    Oct 23 Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%
    Oct 12 Immatics: A Promising TCR Pipeline
    Oct 11 Immatics Advances IMA203 to Phase 3 Trial in Melanoma
    Oct 11 Immatics prices $150M equity offering
    Oct 11 Immatics Announces Pricing of $150 Million Public Offering
    See more IMTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.77
    52 Week Low 7.46
    Average Volume 642,741
    200-Day Moving Average 11.21
    50-Day Moving Average 10.10
    20-Day Moving Average 8.89
    10-Day Moving Average 8.47
    Average True Range 0.42
    RSI (14) 21.26
    ADX 33.43
    +DI 7.69
    -DI 32.91
    Chandelier Exit (Long, 3 ATRs) 8.57
    Chandelier Exit (Short, 3 ATRs) 8.72
    Upper Bollinger Bands 10.03
    Lower Bollinger Band 7.75
    Percent B (%b) 0.02
    BandWidth 25.65
    MACD Line -0.57
    MACD Signal Line -0.49
    MACD Histogram -0.0815
    Fundamentals Value
    Market Cap 803.17 Million
    Num Shares 103 Million
    EPS -1.22
    Price-to-Earnings (P/E) Ratio -6.39
    Price-to-Sales 15.41
    Price-to-Book 4.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 8.45
    Resistance 3 (R3) 8.40 8.15 8.34
    Resistance 2 (R2) 8.15 7.98 8.17 8.30
    Resistance 1 (R1) 7.97 7.88 8.06 8.02 8.27
    Pivot Point 7.72 7.72 7.76 7.74 7.72
    Support 1 (S1) 7.54 7.55 7.63 7.59 7.33
    Support 2 (S2) 7.29 7.45 7.31 7.30
    Support 3 (S3) 7.11 7.29 7.26
    Support 4 (S4) 7.16